Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that this cannabinoid combination did not improve objective sleep duration in the short term. High-density EEG allowed detailed assessment of sleep architecture and next-day alertness, providing more granular data than standard polysomnography. These preliminary findings highlight that cannabinoids marketed as sleep aids may not produce the objective benefits patients expect, and larger controlled trials are needed before clinical recommendations can be made.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG characterization of how a standardized THC/CBD combination affects sleep architecture and objective neurophysiological markers in diagnosed insomnia patients, addressing a critical evidence gap given widespread clinical use of cannabinoids for sleep without adequate mechanistic data. The inclusion of next-day alertness assessment and rigorous polysomnographic methodology enables clinicians to evaluate not only acute sleep effects but also potential daytime impairment, which is essential for safety profiling before broader therapeutic adoption. These findings will inform whether cannabinoid-based interventions warrant inclusion in insomnia treatment algorithms or whether the risk-benefit profile remains unfavorable compared to established pharmacological alternatives.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study contributes useful objective data on cannabinoid effects in insomnia, documenting sleep architecture changes via high-density EEG in a small, female-predominant sample receiving a 10 mg THC and 200 mg CBD combination. The modest sample size and single-dose design limit generalizability, particularly regarding sustained efficacy, dose-response relationships, and applicability to male patients or those with comorbid conditions commonly seen in clinical practice. Importantly, the study examined only acute effects and next-day function, leaving unanswered questions about tolerance development, potential cognitive or psychomotor impacts over longer use, and how this specific THC/CBD ratio compares to other formulations patients may access. While the high-density EEG methodology is a strength, translating EEG-detected sleep stage changes into clinically meaningful improvements in daytime functioning or long-term sleep quality requires larger, longer-duration trials. For now, practitioners considering cannabinoids for insomnia should view this as